Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Seagen Inc. - Common Stock
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seagen Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
17
18
Next >
JMP Securities Maintains Market Outperform Rating for Seagen: Here's What You Need To Know
↗
February 17, 2023
Via
Benzinga
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 16, 2023
Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash.
Via
Benzinga
Why Seagen Stock Is Soaring Today
↗
February 16, 2023
Investors and analysts liked what they heard in the company's Q4 update.
Via
The Motley Fool
Seagen (SGEN) Q4 2022 Earnings Call Transcript
↗
February 15, 2023
SGEN earnings call for the period ending December 31, 2022.
Via
The Motley Fool
8 Analysts Have This to Say About Seagen
↗
February 13, 2023
Via
Benzinga
Analyst Ratings for Seagen
↗
January 20, 2023
Via
Benzinga
Analysts Are Bullish On Seagen's Catalyst-Rich Pipeline, Finding No Problem With No M&A
↗
February 16, 2023
Via
Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
↗
February 16, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
↗
February 16, 2023
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.
Via
Investor's Business Daily
Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday
↗
February 16, 2023
Keybanc boosted the price target for Twilio Inc. (NYSE: TWLO) from $77 to $89. Keybanc analyst Thomas Blakey maintained an Overweight rating on the stock. Twilio shares gained 6.4% to close at $66.05...
Via
Benzinga
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
From
Seagen Inc.
Via
Business Wire
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
February 14, 2023
These stocks may soon start turning heads with their revenue growth.
Via
The Motley Fool
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 13, 2023
From
Seagen Inc.
Via
Business Wire
RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday
↗
February 06, 2023
Citigroup boosted the price target for RH (NYSE: RH) from $305 to $380. Citigroup analyst Steven Zaccone maintained a Buy rating. Hershey shares fell 4% to $330.00 in pre-market trading.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
↗
February 06, 2023
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
↗
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday
↗
January 25, 2023
Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at...
Via
Benzinga
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
↗
January 20, 2023
Via
Benzinga
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
January 19, 2023
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
January 19, 2023
From
Seagen Inc.
Via
Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
↗
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
↗
December 25, 2022
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Via
Benzinga
Seagen to Present at the J.P. Morgan Healthcare Conference
December 20, 2022
From
Seagen Inc.
Via
Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
December 20, 2022
From
Seagen Inc.
Via
Business Wire
Why Seagen Stock Is Trading Higher During Monday's Session
↗
December 12, 2022
Seagen Inc (NASDAQ: SGEN) shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in...
Via
Benzinga
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
December 12, 2022
From
Seagen Inc.
Via
Business Wire
2 Growth Stocks to Buy if the Bear Market Continues in 2023
↗
December 01, 2022
These stocks aren't bargain buys just yet, but they could be soon.
Via
The Motley Fool
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
December 01, 2022
From
Seagen Inc.
Via
Business Wire
Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout
↗
November 21, 2022
Seagen who? Merck is putting its cash to work buying a smaller biotech company.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
